Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC
In a significant development in the field of thoracic oncology, recent findings from the Phase 3 E4512 clinical trial have ...
In a significant development in the field of thoracic oncology, recent findings from the Phase 3 E4512 clinical trial have ...
In a groundbreaking development presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine